QRG Capital Management Inc. Has $4.64 Million Stake in Edwards Lifesciences Corporation $EW

QRG Capital Management Inc. increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,464 shares of the medical research company’s stock after buying an additional 18,172 shares during the period. QRG Capital Management Inc.’s holdings in Edwards Lifesciences were worth $4,643,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of EW. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC lifted its stake in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. boosted its holdings in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $83.98, for a total transaction of $85,575.62. Following the transaction, the vice president owned 33,682 shares of the company’s stock, valued at approximately $2,828,614.36. This represents a 2.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 88,096 shares of company stock worth $7,288,799. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on EW shares. Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, Evercore restated an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Price Performance

EW stock opened at $83.21 on Thursday. The stock has a market cap of $47.97 billion, a PE ratio of 44.26, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87. The stock has a 50-day moving average price of $82.15 and a two-hundred day moving average price of $82.68. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the firm posted $0.64 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.